cropper

The Silver Surfer
Senior Citizens Surfing the Internet

  • Home
  • Categories
    • Health & Wellness
    • Money & Legal
    • Housing & Living
    • Lifestyle & Leisure
    • Technology for Seniors
    • Local Resources
January 16.2026
2 Minutes Read

Are Risky CNS-Active Drugs Still a Concern for Dementia Patients?

Close-up of a weekly pill organizer with CNS-active drugs.

Understanding the Risks of CNS-Active Drugs for Dementia Patients

Dementia patients often face a complex landscape of care, and recent data reveals a concerning trend in medication prescriptions. According to research conducted by John Mafi, MD, and colleagues at UCLA, about one in four dementia patients received prescriptions for central nervous system (CNS)-active drugs, which can have serious side effects.

The Declining Trend of CNS-Active Drug Prescribing

Encouragingly, the prescribing rates for these drugs—mostly benzodiazepines and non-benzodiazepine hypnotics—have dropped significantly over the past nine years, from nearly 20% to 16.2% among older adults. This decline suggests that healthcare providers are making strides toward safer prescribing practices, even as more than two-thirds of the prescriptions lack clear clinical justifications.

Challenges in Dementia Care: What Patients Should Know

Despite reduced prescribing rates, the continued use of potentially inappropriate CNS-active drugs highlights ongoing challenges in dementia care. Patients and caregivers are encouraged to question prescriptions and seek evaluations to ensure that the benefits of medications outweigh the risks involved. Notably, CNS-active drugs can lead to severe side effects such as falls, delirium, and even increased mortality rates in vulnerable dementia patients.

Recognizing the Importance of Non-Pharmacological Treatments

Medical experts advocate for non-pharmacological strategies as the first line of treatment for dementia-related issues. Approaches including cognitive behavioral therapy, physical activity, and social engagement should be prioritized to manage symptoms of agitation and cognitive decline. This patient-centered approach not only enhances the quality of care but also aligns with guidelines from prominent organizations like the American Geriatrics Society.

Tools to Enhance Patient Safety

Healthcare professionals are increasingly utilizing clinical decision support tools embedded in electronic health records. These tools serve as essential resources to alert doctors about potentially inappropriate prescriptions. By fostering awareness among physicians, these tools aim to minimize the risks associated with CNS-active medications.

The Path Forward: What Can be Done?

To ensure safer prescribing practices, it is vital for patients, caregivers, and healthcare providers to communicate openly about treatment plans. Regular reviews of medication can help identify and eliminate any prescriptions that may no longer be necessary or appropriate, reducing the risk of side effects. This proactive step can significantly improve outcomes for dementia patients.

In conclusion, while the progress in reducing unnecessary prescriptions is promising, there is still much work to be done. Continuous education and collaboration among caregivers and healthcare professionals will empower dementia patients to receive better, safer care.

Health & Wellness

10 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
10.17.2026

Exploring Cardiac Microcurrent Therapy: Revolutionary Hope for Heart Failure

Update The Rise of Cardiac Microcurrent Therapy: What You Need to Know In recent discussions surrounding heart health, a groundbreaking therapy called cardiac microcurrent (C-MIC) therapy has emerged as a promising treatment for heart failure (HF). Recent studies presented at the Heart Failure Society of America (HFSA) annual meeting have revealed that C-MIC therapy not only shows potential but may also be beneficial when administered via a less invasive subcutaneous approach. Understanding Cardiac Microcurrent Therapy C-MIC therapy works by delivering microcurrents that aim to improve heart function. This innovative treatment focuses on modifying electrical fields within the heart that are affected by conditions such as myocardial edema and fibrosis—issues commonly faced by patients with heart failure. Initial findings from the C-MIC II trial indicated that C-MIC therapy helped patients demonstrate improved exercise capacity, measured by peak VO2, which indicates the volume of oxygen consumed during exercise. The Clinical Findings are Promising but Met with Skepticism The recent analysis showed that patients receiving C-MIC therapy experienced a notable improvement in their exercise capacity with an increase in weight-adjusted peak VO2. While this sounds incredible, experts like Dr. John Teerlink expressed skepticism regarding the magnitude of these results. As he pointed out, while the improvements are exciting, they warrant further research through larger randomized trials to confirm their reliability and applicability to the broader population. Exploring the Shift to Subcutaneous Delivery One of the most significant developments discussed at the HFSA meeting was the possible shift from surgical implantation to a subcutaneous approach for C-MIC therapy. This new method would involve placing the device under the skin, making it accessible to patients who are not suitable for surgical interventions. Reports from initial trials of this subcutaneous approach indicate that it is equally effective as the traditional method, offering hope to a wider range of patients suffering from heart failure. Why This Matters to Heart Health For millions of individuals living with heart failure, advancements such as C-MIC therapy could mean greater quality of life and increased endurance. A non-invasive treatment option that can be performed in a catheterization lab promises reduced risks and potentially better outcomes for patients seeking relief from this chronic condition. Final Thoughts: What Lies Ahead for C-MIC Therapy As the healthcare community looks toward larger studies to validate these results, patients and caregivers should remain informed about the potential benefits and limitations of C-MIC therapy. With advancements in heart failure treatments promising new possibilities, it's crucial to stay connected with healthcare professionals to better understand the best options available. In conclusion, while the excitement surrounding cardiac microcurrent therapy grows, the importance of rigorous research cannot be overstated. Continued discussion around efficacy, accessibility, and patient outcomes will ensure that heart failure treatments evolve to meet patient needs effectively.

10.17.2026

New Radiotracer 124I-evuzamitide Enhances Early Cardiac Amyloidosis Detection

Update Revolutionizing Detection of Cardiac Amyloidosis PHOENIX -- A new study has revealed groundbreaking advancements in detecting cardiac amyloidosis, a condition where an abnormal protein builds up in the heart. A promising tracer, 124I-evuzamitide, showcased its capabilities in identifying this disease during early stages, particularly in cases with low protein levels, in a phase III clinical trial known as REVEAL. This study, presented by Dr. Mathew Maurer at the Heart Failure Society of America annual meeting, marks a noteworthy stride in cardiovascular diagnostics. Reliable Detection with New Tracer The 124I-evuzamitide tracer achieved remarkable reliability, demonstrating a sensitivity of 93.5% and a specificity of 86.0% for identifying cardiac amyloidosis in patients suspected of having the disease. With a negative predictive value of 94.1% and a positive predictive value of 84.7%, this new agent significantly outperformed traditional methods such as bone scintigraphy, particularly in early detection of transthyretin amyloidosis (ATTR). Importance of Early Diagnosis Dr. Maurer emphasized the critical nature of early detection in providing timely treatment options. In the study, the tracer outperformed bone scintigraphy, detecting ATTR cases with a high degree of accuracy, even when conventional methods fell short. Early diagnosis could lead to timely intervention with available disease-modifying therapies like tafamidis, significantly benefiting patient outcomes. Impact on Patients and Next Steps This new approach addresses a common frustration expressed by patients regarding their condition: understanding the extent of amyloid buildup and monitoring its progression. The investigational tracer not only enables accurate diagnostics but also offers a method for tracking the amyloid load over time. According to Dr. Maurer, these insights could allow doctors to answer pressing patient questions about their health more effectively. Future Directions: Regulatory Approval in Sight Due to the compelling results from the REVEAL study, Bayer plans to seek regulatory approval for the 124I-evuzamitide tracer. As the medical community anticipates a new standard diagnostic tool, the hope is that this tracer will pave the way for changing the landscape of cardiac amyloidosis management. The implications of this study are profound. By harnessing the power of innovative tracers, healthcare providers can enhance diagnostic accuracy and optimize treatment routes, maximizing the potential for improved health outcomes for those living with cardiac amyloidosis.

10.16.2026

Understanding the Setbacks of PDE9 Inhibition in Heart Failure Treatments

Update The Road Ahead for PDE9 Inhibition in Heart Failure In a recent presentation at the Heart Failure Society of America (HFSA) annual meeting, Dr. James Udelson, an expert from Tufts Medical Center, discussed the challenges faced during the development of tovinontrine, a PDE9 inhibitor aimed at treating heart failure. Two phase II placebo-controlled trials, CYCLE-1 and CYCLE-2, encountered significant setbacks, leading researchers to question whether the doses administered were optimal. Why Did These Trials Fall Short? Both trials aimed to test the effectiveness of tovinontrine on NT-proBNP levels, a key indicator used to assess heart failure severity. In the CYCLE-1 trial focused on heart failure with reduced ejection fraction (HFrEF), the drug only managed a nonsignificant average reduction of NT-proBNP by 4.4% at the highest tested dose of 50 mg. Interestingly, a lower dose of 25 mg showed a more promising drop of 10.8%. Similarly, CYCLE-2's results were disappointing; the 50 mg dose caused NT-proBNP levels to rise by 1.7% against a substantial fall of 10.1% in the placebo group. A Closer Look at the Dosing Dilemma The disparities in efficacy suggest that the higher doses may not have been suitable for eliciting the desired impact. Udelson candidly acknowledged, "Did we have the wrong dose? Yes, that's pretty clear." The data gleaned from CYCLE-1 revealed an inverse dose response, where a much lower dose (2.5 mg) resulted in a notable 16% reduction in NT-proBNP levels, signaling a potential need for cautious dosing strategies in future trials. New Horizons on the CYCLE-3 Trail The upcoming CYCLE-3 trial, scheduled for 2027, aims to investigate the effects of this lower dose further. Udelson hypothesizes that lower doses will result in less intense inhibition of PDE9, minimizing adverse impacts on cGMP levels, which appear to reach a ceiling beyond which cardiac improvements stall. The goal is to find a beneficial middle ground where lowering tovinontrine doses may enhance NT-proBNP reductions, ultimately leading to improved patient outcomes. Why PDE9 Inhibition Matters Understanding PDE9 inhibition is crucial since elevated PDE9 expression has been observed in heart failure patients, particularly those with heart failure with preserved ejection fraction (HFpEF). Preliminary results from the CARDINAL-HF trial indicated that PDE9 inhibition does elevate cGMP levels without significant safety issues, reinforcing interest in this therapeutic approach. The Future of Heart Failure Treatment With heart failure on the rise as a significant public health concern, researchers are hopeful that a better understanding of dosage and the physiological mechanisms involved will lead to effective treatments. As the field shifts toward more individualized therapeutic strategies, the lessons learned from these trials could pave the way for revolutionary advancements in heart failure management.

Silver Surfer Media

A division of

Electronic Commerce Engineering Corporation

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

+19085200096

AVAILABLE FROM 9AM - 5PM

Monday ~ Friday

Green Township, New Jersey

 07860-5406

ABOUT US

The Sussex County Advisor is operated by synergetic.media a subsidiary of  Electronic Commerce Engineering Corporation, Green Township, NJ 07860-5406

© 2026 Electronic Commerce Engineering Corporation All Rights Reserved. 16 Wintermute Rd, Green Township, NJ 07860-5406 . Contact Us . Terms of Service . Privacy Policy

{"company":"Electronic Commerce Engineering Corporation","address":"16 Wintermute Rd","city":"Green Township","state":"NJ","zip":"07860-5406","email":"info@ecommerceengineering.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*